{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:30:30Z","timestamp":1773113430496,"version":"3.50.1"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Unlike substantial evidence in the prevention of chemotherapy-induced nausea and vomiting (CINV), research in the prevention of nausea and vomiting caused by concurrent chemoradiotherapy (CCRT) is currently lacking.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare the efficacy and safety of fosaprepitant weekly vs every 3 weeks for the prevention of nausea and emesis caused by CCRT among patients with nasopharyngeal carcinoma.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This pilot randomized clinical trial was conducted at a single cancer center from November 24, 2020, to July 26, 2021, among patients with nasopharyngeal carcinoma who had achieved CINV control after 2 to 3 cycles of induction chemotherapy. Efficacy analyses were performed in the intention-to-treat population. Data were analyzed on November 4, 2022.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Eligible patients were randomly assigned (1:1) to receive fosaprepitant either weekly or every 3 weeks.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary end point was the proportion of patients with sustained complete response (defined as no emesis and no rescue therapy) during CCRT. Secondary end points were sustained no emesis, no nausea, no significant nausea, mean time to first emetic episode, quality of life, and 1-year progression-free survival (PFS).<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 100 patients (mean [SD] age, 46.6 [10.9] years; 83 [83.0%] male) who had achieved CINV control after induction chemotherapy were randomly assigned to receive fosaprepitant weekly (50 patients) or every 3 weeks (50 patients). There was no significantly significant difference in cumulative risk of emesis or rescue therapy in the group that received weekly fosaprepitant compared with those who received fosaprepitant every 3 weeks (subhazard ratio, 0.66 [95% CI, 0.43-1.02]; P<\/jats:italic>\u2009=\u2009.06). The proportion of patients with sustained no emesis (38% vs 14%; P<\/jats:italic>\u2009=\u2009.003) or no significant nausea (92% vs 72%; P<\/jats:italic>\u2009=\u2009.002) was significantly higher in the group that received fosaprepitant weekly vs those who received fosaprepitant every 3 weeks. Treatments were well tolerated. Patients in the weekly group had improved scores for multiple quality-of-life measures. There was no significant difference in survival outcomes between groups (91.8% vs 93.7%; P<\/jats:italic>\u2009=\u2009.99). In the mean brainstem dose subgroups, a possible treatment interaction effect was observed in sustained complete response (mean brainstem dose \u226536 Gy: hazard ratio [HR], 0.32 [95% CI, 0.15-0.69]; mean brainstem dose &amp;lt;36 Gy: HR, 0.95 [95% CI, 0.55-1.63]) and sustained no emesis (mean brainstem dose \u226536 Gy: HR, 0.21 [95% CI, 0.08-0.53]; mean brainstem dose &amp;lt;36 Gy: HR, 0.73 [95% CI, 0.41-1.28]).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this pilot randomized clinical trial, there was no statistically significant difference in the complete response primary end point, but patients receiving weekly fosaprepitant were less likely to experience emesis compared with those who received fosaprepitant every 3 weeks, especially in the subgroup with a mean brainstem dose of 36 Gy or more. Weekly fosaprepitant was well tolerated and improved quality of life of patients without compromising survival.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT04636632<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.26127","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T15:32:38Z","timestamp":1690471958000},"page":"e2326127","source":"Crossref","is-referenced-by-count":3,"title":["Fosaprepitant Weekly vs Every 3 Weeks for the Prevention of Concurrent Chemoradiotherapy\u2013Induced Nausea and Vomiting"],"prefix":"10.1001","volume":"6","author":[{"given":"Qi","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiong","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Long","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Feng","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Long","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong-Yang","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"You","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Ping","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Zeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Yu","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Jun","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Yuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"issue":"4","key":"zoi230751r1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(15)00615-4","article-title":"Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.","volume":"17","author":"Ruhlmann","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"zoi230751r2","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0360-3016(99)00055-3","article-title":"Radiation-induced emesis: a prospective observational multicenter Italian trial.","volume":"44","author":"The Italian Group for Antiemetic Research in Radiotherapy","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"zoi230751r3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.radonc.2009.11.001","article-title":"A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres.","volume":"94","author":"Maranzano","year":"2010","journal-title":"Radiother Oncol"},{"issue":"1","key":"zoi230751r4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/hed.v42.1","article-title":"Radiation-induced nausea and vomiting in head and neck cancer: Is it something worth considering in the intensity modulated radiotherapy era: a narrative review.","volume":"42","author":"Paiar","year":"2020","journal-title":"Head Neck"},{"issue":"2","key":"zoi230751r5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0360-3016(92)90768-D","article-title":"Loss of local control with prolongation in radiotherapy.","volume":"23","author":"Fowler","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"zoi230751r6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0360-3016(97)00716-5","article-title":"Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers.","volume":"40","author":"Robertson","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"zoi230751r7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00520-016-3407-8","article-title":"2016 updated MASCC\/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting.","volume":"25","author":"Ruhlmann","year":"2017","journal-title":"Support Care Cancer"},{"key":"zoi230751r8","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"zoi230751r9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.radonc.2014.02.019","article-title":"Beam path toxicity in candidate organs-at-risk: assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy.","volume":"111","author":"Kocak-Uzel","year":"2014","journal-title":"Radiother Oncol"},{"issue":"4","key":"zoi230751r10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.prro.2013.08.003","article-title":"Dorsal vagal complex of the brainstem: conformal avoidance to reduce nausea.","volume":"4","author":"Monroe","year":"2014","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"zoi230751r11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.meddos.2009.11.002","article-title":"Effect of brain stem and dorsal vagus complex dosimetry on nausea and vomiting in head and neck intensity-modulated radiation therapy.","volume":"36","author":"Ciura","year":"2011","journal-title":"Med Dosim"},{"issue":"4","key":"zoi230751r12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s13566-013-0094-7","article-title":"Correlation of planned dose to area postrema and dorsal vagal complex with clinical symptoms of nausea and vomiting in oropharyngeal cancer (OPC) patients treated with radiation alone using IMRT.","volume":"2","author":"Wang","year":"2013","journal-title":"J Radiat Oncol"},{"issue":"1","key":"zoi230751r13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ijrobp.2011.10.010","article-title":"Dosimetric predictors of radiation-induced acute nausea and vomiting in IMRT for nasopharyngeal cancer.","volume":"84","author":"Lee","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"zoi230751r15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.927510","article-title":"Induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis.","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"zoi230751r16","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1021\/jm990617v","article-title":"Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.","volume":"43","author":"Hale","year":"2000","journal-title":"J Med Chem"},{"issue":"11","key":"zoi230751r17","first-page":"1367","article-title":"Substance P receptor antagonist I: conversion of phosphoramidate prodrug after i.v. administration to rats and dogs.","volume":"27","author":"Huskey","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"zoi230751r18","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0028-3908(99)00172-0","article-title":"The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets.","volume":"39","author":"Tattersall","year":"2000","journal-title":"Neuropharmacology"},{"issue":"1","key":"zoi230751r19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cne.903430107","article-title":"Distribution of substance P-like immunoreactive neurons and terminals throughout the nucleus of the solitary tract in the human brainstem.","volume":"343","author":"McRitchie","year":"1994","journal-title":"J Comp Neurol"},{"issue":"8","key":"zoi230751r20","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0028-3908(96)00020-2","article-title":"Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets.","volume":"35","author":"Tattersall","year":"1996","journal-title":"Neuropharmacology"},{"issue":"2","key":"zoi230751r21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/(SICI)1096-9861(19981214)402:2<181::AID-CNE4>3.0.CO;2-B","article-title":"Cellular and subcellular distribution of substance P receptor immunoreactivity in the dorsal vagal complex of the rat and cat: a light and electron microscope study.","volume":"402","author":"Baude","year":"1998","journal-title":"J Comp Neurol"},{"issue":"2","key":"zoi230751r22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0304-3940(00)01113-7","article-title":"The role of tachykinin NK-1 receptors in the area postrema of ferrets in emesis.","volume":"286","author":"Ariumi","year":"2000","journal-title":"Neurosci Lett"},{"issue":"2","key":"zoi230751r23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0028-3908(99)00113-6","article-title":"The effect of the NK1 receptor antagonist CP-99,994 on emesis and c-fos protein induction by loperamide in the ferret.","volume":"39","author":"Zaman","year":"2000","journal-title":"Neuropharmacology"},{"issue":"1-2","key":"zoi230751r24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0304-3940(01)02269-8","article-title":"The anti-emetic action of the neurokinin(1) receptor antagonist CP-99,994 does not require the presence of the area postrema in the dog.","volume":"314","author":"Andrews","year":"2001","journal-title":"Neurosci Lett"},{"issue":"2","key":"zoi230751r25","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ijrobp.2017.10.013","article-title":"Randomized, double-blind, placebo-controlled trial of Shuanghua Baihe tablets to prevent oral mucositis in patients with nasopharyngeal cancer undergoing chemoradiation therapy.","volume":"100","author":"Zheng","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"zoi230751r26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.radonc.2012.08.013","article-title":"A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma.","volume":"104","author":"Peng","year":"2012","journal-title":"Radiother Oncol"},{"key":"zoi230751r27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.radonc.2021.07.024","article-title":"A randomized, controlled phase II trial of maxillofacial and oral massage in attenuating severe radiotherapy-induced oral mucositis and lipid metabolite changes in nasopharyngeal carcinoma.","volume":"163","author":"Yang","year":"2021","journal-title":"Radiother Oncol"},{"issue":"10","key":"zoi230751r28","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1007\/s00520-019-4643-5","article-title":"Efficacy of controlled-release oxycodone for reducing pain due to oral mucositis in nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy: a prospective clinical trial.","volume":"27","author":"Hua","year":"2019","journal-title":"Support Care Cancer"},{"issue":"2","key":"zoi230751r29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00265968","article-title":"Assessment of nausea.","volume":"38","author":"Del Favero","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"issue":"14","key":"zoi230751r30","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/S0959-8049(00)00186-6","article-title":"A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients.","volume":"36","author":"Bjordal","year":"2000","journal-title":"Eur J Cancer"},{"key":"zoi230751r31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1471-2288-13-87","article-title":"Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia.","volume":"13","author":"Yap","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"zoi230751r32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2016.12.039","article-title":"Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial.","volume":"75","author":"Cao","year":"2017","journal-title":"Eur J Cancer"},{"issue":"3","key":"zoi230751r33","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ijrobp.2008.01.012","article-title":"Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer.","volume":"72","author":"Rosenthal","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"zoi230751r34","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1007\/s00520-013-1926-0","article-title":"Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin-a phase II study.","volume":"21","author":"Ruhlmann","year":"2013","journal-title":"Support Care Cancer"},{"issue":"7","key":"zoi230751r35","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/annonc\/mdu096","article-title":"A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.","volume":"25","author":"Gralla","year":"2014","journal-title":"Ann Oncol"},{"issue":"7","key":"zoi230751r36","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/cncr.21343","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.","volume":"104","author":"Herrstedt","year":"2005","journal-title":"Cancer"},{"issue":"22","key":"zoi230751r37","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","article-title":"The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2014the Aprepitant Protocol 052 Study Group.","volume":"21","author":"Hesketh","year":"2003","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi230751r38","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/cncr.11433","article-title":"Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America.","volume":"97","author":"Poli-Bigelli","year":"2003","journal-title":"Cancer"},{"issue":"9","key":"zoi230751r39","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S1470-2045(15)00035-2","article-title":"Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.","volume":"16","author":"Rapoport","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"zoi230751r40","first-page":"1","article-title":"Clinical roundtable monograph: new data in emerging treatment options for chemotherapy-induced nausea and vomiting.","volume":"12","author":"Morrow","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"issue":"10","key":"zoi230751r41","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cncr.20230","article-title":"Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.","volume":"100","author":"Grunberg","year":"2004","journal-title":"Cancer"},{"issue":"12","key":"zoi230751r42","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.","volume":"23","author":"Warr","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi230751r43","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/annonc\/mds541","article-title":"Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.","volume":"24","author":"Saito","year":"2013","journal-title":"Ann Oncol"},{"key":"zoi230751r14","article-title":"","author":"Fan"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2807658\/yang_2023_oi_230751_1689708831.64299.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T15:32:59Z","timestamp":1690471979000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2807658"}},"subtitle":["A Pilot Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.26127","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]}}}